Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried

Taking stock of the drug industry, from the lab to the medicine chest

June 13, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried A wonky policy shift in the arcane world of "health technology assessments" has drugmakers big and small racing to adapt. By Andrew Joseph Supreme Court unanimously rejects challenge to mailed abortion pills The judges unanimously rejected a challenge to an FDA decision to expand access to abortion pills by mail. By Sarah Owermohle Biopharma execs cheer Supreme Court for upholding FDA authority in abortion pill case The effort to ban the mailing of abortion pill mifepristone was a serious challenge to FDA's authority. By Sarah Owermohle, Allison DeAngelis, and Adam Feuerstein Evan Vucci/AP Biden and Trump are fighting to claim credit for $35 insulin. It was actually a pharma giant's idea The pharma giant Eli Lilly first proposed $35 insulin for Medicare patients, an idea later adopted by both Biden and Trump. By Rachel Cohrs Zhang STAT+ | Will Geron be acquired? The long-short view This week in biotechnology: Adam Feuerstein's subscriber-only newsletter digs into Geron and Candel Therapeutics. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser